Tenax Therapeutics (NASDAQ:TENX) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note released on Thursday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Price Performance

Shares of NASDAQ TENX traded down $0.12 during midday trading on Thursday, hitting $3.08. 17,899 shares of the company’s stock traded hands, compared to its average volume of 162,274. The firm has a fifty day moving average of $3.31 and a 200 day moving average of $4.61. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last released its earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.72). Equities research analysts anticipate that Tenax Therapeutics will post -7.96 earnings per share for the current year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.